Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure
- PMID: 29525225
- DOI: 10.1016/j.diabet.2017.10.007
Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure
Abstract
Aims: It is well-known that chronic exposure to large amounts of ligand leads to downregulation of its receptor. It is not known, however, whether a GLP-1R agonist downregulates its receptor. For this reason, our study examined whether GLP-1R expression is reduced after long-term exposure to dulaglutide (Dula) in non-diabetic and diabetic mice.
Methods: Seven-week-old male db/db and db/m mice were given either Dula (0.6mg/kg×2/week) or a control vehicle (CTL) for 17 weeks. Various metabolic parameters, such as glucose-stimulated insulin secretion (GSIS), insulin and TG content in islets, were evaluated after the intervention. β-cell-related gene expression was also analyzed by real-time RT-PCR.
Results: In db/m mice, GLP-1R expression in β-cells did not decrease, not even after long-term administration of Dula, compared with control mice, while GLP-1R expression in 24-week-old db/db mice treated with Dula was augmented, rather than downregulated, compared with 24-week-old CTL db/db mice. This was probably due to improved glycaemic control. In db/db mice treated with Dula, food intake and blood glucose levels were significantly decreased up to 24 weeks of age compared with CTL db/db mice, and their expression levels of various β-cell-related genes, insulin content and GSIS were also enhanced. In contrast, oxidative and endoplasmic reticulum stress, inflammation, fibrosis and apoptosis were suppressed with Dula treatment.
Conclusion: Dula exerts beneficial effects on glycaemic control and has long-lasting protective effects on pancreatic β-cells. GLP-1R expression levels were not reduced at all in non-diabetic as well as diabetic mice despite long-term dulaglutide exposure.
Keywords: Apoptosis; Cell proliferation; Dulaglutide; Durability; GLP-1 receptor; β-cell.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db/db mice.Cell Signal. 2025 Mar;127:111603. doi: 10.1016/j.cellsig.2025.111603. Epub 2025 Jan 11. Cell Signal. 2025. PMID: 39805329
-
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.Diabetes Obes Metab. 2016 Aug;18(8):834-9. doi: 10.1111/dom.12671. Epub 2016 May 16. Diabetes Obes Metab. 2016. PMID: 27059816
-
The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type Ⅱ collagen and aggrecan in human SW1353 chondrocytes.Chem Biol Interact. 2020 May 1;322:108968. doi: 10.1016/j.cbi.2020.108968. Epub 2020 Jan 29. Chem Biol Interact. 2020. PMID: 32004530
-
[Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].Nihon Yakurigaku Zasshi. 2015 Oct;146(4):215-24. doi: 10.1254/fpj.146.215. Nihon Yakurigaku Zasshi. 2015. PMID: 26656966 Review. Japanese. No abstract available.
-
GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Pharmacotherapy. 2014 Nov;34(11):1174-86. doi: 10.1002/phar.1507. Pharmacotherapy. 2014. PMID: 25382096 Review.
Cited by
-
Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.Brain Behav. 2024 Mar;14(3):e3448. doi: 10.1002/brb3.3448. Brain Behav. 2024. PMID: 38444330 Free PMC article.
-
Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies.Int J Mol Sci. 2021 May 18;22(10):5303. doi: 10.3390/ijms22105303. Int J Mol Sci. 2021. PMID: 34069914 Free PMC article. Review.
-
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.Front Endocrinol (Lausanne). 2021 Aug 6;12:714447. doi: 10.3389/fendo.2021.714447. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34484124 Free PMC article.
-
Evaluating the Overall Safety of Glucokinase Activators in Patients with Type 2 Diabetes Mellitus.Diabetes Metab Syndr Obes. 2024 Nov 28;17:4539-4552. doi: 10.2147/DMSO.S474280. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 39629068 Free PMC article. Review.
-
Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine.Int J Mol Sci. 2021 Jul 24;22(15):7917. doi: 10.3390/ijms22157917. Int J Mol Sci. 2021. PMID: 34360682 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous